Pharmacotherapy of social anxiety disorder.
Publication
, Journal Article
Davidson, JR
Published in: J Clin Psychiatry
1998
Antidepressants and high-potency benzodiazepines have been used successfully to treat patients with social anxiety disorder. This review considers the efficacy of irreversible and reversible inhibitors of monoamine oxidase, selective serotonin reuptake inhibitors, high-potency benzodiazepines, and beta-blockers and presents the response rates for each of these classes. Aspects of the social anxiety syndrome that are sensitive to drug treatment are discussed, and the data relating to relapse following treatment discontinuation are presented. Predictors for negative treatment outcome following completion of acute treatment trials are reviewed.
Duke Scholars
Published In
J Clin Psychiatry
ISSN
0160-6689
Publication Date
1998
Volume
59 Suppl 17
Start / End Page
47 / 53
Location
United States
Related Subject Headings
- Treatment Outcome
- Selective Serotonin Reuptake Inhibitors
- Recurrence
- Psychiatry
- Prognosis
- Phobic Disorders
- Multicenter Studies as Topic
- Monoamine Oxidase Inhibitors
- Humans
- Clinical Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Davidson, J. R. (1998). Pharmacotherapy of social anxiety disorder. J Clin Psychiatry, 59 Suppl 17, 47–53.
Davidson, J. R. “Pharmacotherapy of social anxiety disorder.” J Clin Psychiatry 59 Suppl 17 (1998): 47–53.
Davidson JR. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998;59 Suppl 17:47–53.
Davidson, J. R. “Pharmacotherapy of social anxiety disorder.” J Clin Psychiatry, vol. 59 Suppl 17, 1998, pp. 47–53.
Davidson JR. Pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 1998;59 Suppl 17:47–53.
Published In
J Clin Psychiatry
ISSN
0160-6689
Publication Date
1998
Volume
59 Suppl 17
Start / End Page
47 / 53
Location
United States
Related Subject Headings
- Treatment Outcome
- Selective Serotonin Reuptake Inhibitors
- Recurrence
- Psychiatry
- Prognosis
- Phobic Disorders
- Multicenter Studies as Topic
- Monoamine Oxidase Inhibitors
- Humans
- Clinical Trials as Topic